{"id":"https://openalex.org/W4310106246","doi":"https://doi.org/10.1182/blood-2022-170647","title":"Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study","display_name":"Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study","publication_year":2022,"publication_date":"2022-11-15","ids":{"openalex":"https://openalex.org/W4310106246","doi":"https://doi.org/10.1182/blood-2022-170647"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2022-170647","doi":"https://doi.org/10.1182/blood-2022-170647","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-170647","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5067453905","display_name":"Emily M. Geramita","orcid":"https://orcid.org/0000-0001-6387-4950","observed_orcids":["https://orcid.org/0000-0001-6387-4950"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Geramita","raw_affiliation_strings":["1University of Pittsburgh Medical Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100370972","display_name":"Hong Wang","orcid":"https://orcid.org/0000-0003-0477-2908","observed_orcids":["https://orcid.org/0000-0003-0477-2908"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Wang","raw_affiliation_strings":["1University of Pittsburgh Medical Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5013879650","display_name":"Melissa L. Bastacky","orcid":"https://orcid.org/0000-0001-7573-2669","observed_orcids":["https://orcid.org/0000-0001-7573-2669"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Melissa Bastacky","raw_affiliation_strings":["1University of Pittsburgh Medical Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056495862","display_name":"Jessica B Cohen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jessica Cohen","raw_affiliation_strings":["1University of Pittsburgh Medical Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210134769"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091021372","display_name":"Rory Michael Shallis","orcid":"https://orcid.org/0000-0002-8542-2944","observed_orcids":["https://orcid.org/0000-0002-8542-2944"]},"institutions":[{"id":"https://openalex.org/I32971472","display_name":"Yale University","ror":"https://ror.org/03v76x132","country_code":"US","type":"education","lineage":["https://openalex.org/I32971472"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rory Michael Shallis","raw_affiliation_strings":["2Yale University School of Medicine, New Haven, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Yale University School of Medicine, New Haven, CT","institution_ids":["https://openalex.org/I32971472"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079157559","display_name":"Talha Badar","orcid":"https://orcid.org/0000-0003-1548-918X","observed_orcids":["https://orcid.org/0000-0003-1548-918X"]},"institutions":[{"id":"https://openalex.org/I4210146710","display_name":"Mayo Clinic in Florida","ror":"https://ror.org/03zzw1w08","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723","https://openalex.org/I4210146710"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Talha Badar","raw_affiliation_strings":["3Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Hematology and Oncology, Mayo Clinic Florida, Jacksonville, FL","institution_ids":["https://openalex.org/I4210146710"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085360755","display_name":"Mark Robert Litzow","orcid":"https://orcid.org/0000-0002-9816-6302","observed_orcids":["https://orcid.org/0000-0002-9816-6302"]},"institutions":[{"id":"https://openalex.org/I1330342723","display_name":"Mayo Clinic","ror":"https://ror.org/02qp3tb03","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1330342723"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark R. Litzow","raw_affiliation_strings":["4Division of Hematology, Mayo Clinic, Rochester, MN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Division of Hematology, Mayo Clinic, Rochester, MN","institution_ids":["https://openalex.org/I1330342723"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083465867","display_name":"Annie Im","orcid":"https://orcid.org/0000-0002-0973-7100","observed_orcids":["https://orcid.org/0000-0002-0973-7100"]},"institutions":[{"id":"https://openalex.org/I4210134769","display_name":"University of Pittsburgh Medical Center","ror":"https://ror.org/04ehecz88","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210098814","https://openalex.org/I4210134769"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Annie Im","raw_affiliation_strings":["1University of Pittsburgh Medical Center, Pittsburgh, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1University of Pittsburgh Medical Center, Pittsburgh, PA","institution_ids":["https://openalex.org/I4210134769"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2500,"currency":"USD","value_usd":2500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.2364847,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"140","issue":"Supplement 1","first_page":"6187","last_page":"6188"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-acute-myeloid-leukemia","display_name":"relapsed/refractory acute myeloid leukemia","score":0.9810000061988831},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.8989999890327454},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.9919999837875366},{"id":"https://openalex.org/keywords/azacitidine","display_name":"azacitidine","score":0.9860000014305115},{"id":"https://openalex.org/keywords/decitabine","display_name":"decitabine","score":1.0},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.9700000286102295},{"id":"https://openalex.org/keywords/complete-remission","display_name":"complete remission","score":0.9190000295639038},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7889999747276306},{"id":"https://openalex.org/keywords/prognostic-factors","display_name":"prognostic factors","score":0.7590000033378601},{"id":"https://openalex.org/keywords/secondary-acute-myeloid-leukemia","display_name":"secondary acute myeloid leukemia","score":0.46399998664855957},{"id":"https://openalex.org/keywords/therapy-related-aml","display_name":"therapy-related AML","score":0.7360000014305115},{"id":"https://openalex.org/keywords/cytogenetic-risk","display_name":"cytogenetic risk","score":0.45399999618530273},{"id":"https://openalex.org/keywords/flt3-itd-mutation","display_name":"FLT3-ITD","score":0.6840000152587891},{"id":"https://openalex.org/keywords/npm1-mutation","display_name":"NPM1 mutation","score":0.6340000033378601},{"id":"https://openalex.org/keywords/dnmt3a-mutation","display_name":"DNMT3A mutation","score":0.6899999976158142}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.7901711463928223},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7505804300308228},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.615421712398529},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4815950095653534},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4637848138809204},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.4462767243385315},{"id":"https://openalex.org/C2780775027","wikidata":"https://www.wikidata.org/wiki/Q17141389","display_name":"Salvage therapy","level":3,"score":0.43752893805503845},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.43499118089675903},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.4340887665748596},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.4272539019584656},{"id":"https://openalex.org/C9583187","wikidata":"https://www.wikidata.org/wiki/Q7919510","display_name":"Ven","level":2,"score":0.4139039218425751},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3709285259246826},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.26933425664901733},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.09949129819869995},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C38652104","wikidata":"https://www.wikidata.org/wiki/Q3510521","display_name":"Computer security","level":1,"score":0.0},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2022-170647","doi":"https://doi.org/10.1182/blood-2022-170647","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2022-170647","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2985247963","https://openalex.org/W4200422538","https://openalex.org/W4229070734","https://openalex.org/W4281671725","https://openalex.org/W4310107812","https://openalex.org/W3080879632","https://openalex.org/W3213771558","https://openalex.org/W3216817653","https://openalex.org/W4394759173","https://openalex.org/W4310120160"],"abstract_inverted_index":{"BACKGROUND:":[0],"Despite":[1],"recent":[2],"advances":[3],"in":[4,68,287,542,556,619],"treatment":[5],"options":[6],"for":[7,17,51,56,94,135,221,230,240,378,441],"relapsed/refractory":[8],"(R/R)":[9],"acute":[10],"myeloid":[11],"leukemia":[12,195],"(AML),":[13],"prognosis":[14],"remains":[15],"poor":[16],"patients":[18,129,286,314,377,543,557],"who":[19,53,544,558],"do":[20],"not":[21,560,596],"proceed":[22],"to":[23,81,98,256,386,418,581,590,627,643],"allogeneic":[24],"stem":[25],"cell":[26],"transplant.":[27],"In":[28,74,566],"the":[29,32,69,83,157,165,248,262,268,272,284,461,481],"frontline":[30],"setting,":[31],"combination":[33],"of":[34,49,101,127,142,156,189,211,252,336,375,383,398,420,445,483,527,608,647],"a":[35,46,106,119,373,439,442,546,562],"hypomethylating":[36],"agent":[37],"with":[38,64,87,131,181,214,278,325,331,344,349,357,362,368,423,532,575,586],"venetoclax":[39],"(HMA":[40],"+":[41,66,89,133,191,193,254,294,301,388,425,485,487,540,577,613],"ven)":[42],"has":[43],"emerged":[44],"as":[45,91,234,236,247,340,641],"new":[47],"standard":[48],"care":[50],"adults":[52],"are":[54,625],"unfit":[55],"intensive":[57],"chemotherapy.":[58],"However,":[59],"data":[60,380],"on":[61,113,381],"response":[62,84,167,644,648],"rates":[63,509,574,584],"HMA":[65,88,132,253,387,424,539,576,612],"ven":[67,90,134,255,295,389,426,541,578,614],"R/R":[70,95,136,592],"setting":[71],"is":[72],"limited.":[73],"this":[75,567,620,635],"multicenter":[76,107,568],"retrospective":[77,108,569],"analysis,":[78,289,570],"we":[79],"sought":[80],"estimate":[82],"rate":[85,186,188,213,444,453,464,473,482,521,534,602],"associated":[86,531],"salvage":[92,421],"therapy":[93,173,384,422],"AML":[96,137,306,318,327],"and":[97,116,187,202,225,271,296,328,365,406,460,480,504,506,512,522,572,603,637,645],"explore":[99],"predictors":[100],"response.":[102],"METHODS:":[103],"We":[104,152,163,594],"conducted":[105],"study":[109,158],"through":[110],"COMMAND":[111],"(Consortium":[112],"Myeloid":[114],"Malignancies":[115],"Neoplastic":[117],"Diseases),":[118],"collaboration":[120],"involving":[121],"10":[122],"academic":[123],"institutions.":[124],"A":[125],"total":[126],"93":[128,285],"treated":[130],"at":[138,168,305,538],"3":[139,410],"sites":[140],"(University":[141],"Pittsburgh":[143],"Medical":[144],"Center,":[145],"Yale,":[146],"Mayo":[147],"Clinic":[148],"Florida)":[149],"were":[150,510,516,579],"evaluated.":[151],"summarized":[153],"clinical":[154,652],"characteristics":[155],"population":[159],"using":[160,219],"descriptive":[161],"statistics.":[162],"reported":[164,585],"best":[166],"any":[169,259],"point":[170],"after":[171],"starting":[172],"by":[174,199,267,322],"summarizing":[175],"complete":[176],"remission":[177],"(CR)":[178],"rate,":[179],"CR":[180,190,212,443,452,463,484,520,533,547,571,583,601],"incomplete":[182],"count":[183],"recovery":[184],"(CRi)":[185],"CRi":[192,472,486],"morphologic":[194],"free":[196],"state":[197],"(MLFS)":[198],"frequency":[200],"(percentage)":[201],"its":[203,279],"exact":[204,238],"95%":[205,280],"confidence":[206],"interval":[207],"(CI).":[208],"The":[209,334,413,450,471],"association":[210,599],"continuous":[215],"variables":[216,224],"was":[217,265,275,308,339,390,427,454,465,474,489,497,530,548],"examined":[218],"t-tests":[220],"normally":[222],"distributed":[223,232],"Wilcoxon":[226],"rank":[227],"sum":[228],"tests":[229],"non-normally":[231],"variables,":[233],"well":[235],"Fisher's":[237],"test":[239],"categorical":[241],"variables.":[242],"Overall":[243],"survival":[244],"(OS),":[245],"defined":[246],"time":[249,415,642],"from":[250,258,416,634],"start":[251,419],"death":[257],"cause":[260],"or":[261,353,525,606],"last":[263],"follow-up,":[264],"analyzed":[266],"Kaplan-Meier":[269],"method,":[270],"median":[273,414],"OS":[274,496,508,573],"calculated":[276],"along":[277],"CI.":[281],"RESULTS:":[282],"Among":[283,372],"our":[288],"63%":[290],"(n=59)":[291],"received":[292,299,394,402,409],"azacitidine":[293],"37%":[297],"(n=34)":[298],"decitabine":[300],"ven.":[302],"Median":[303,495],"age":[304,537],"diagnosis":[307,417],"61":[309],"years":[310,551,555],"(IQR":[311,430],"54-69).":[312],"Most":[313],"had":[315],"de":[316],"novo":[317],"(59%,":[319],"n=55),":[320],"followed":[321],"31%":[323],"(n=29)":[324],"secondary":[326],"10%":[329,347],"(n=9)":[330],"therapy-related":[332],"AML.":[333,528,593],"distribution":[335],"cytogenetic/molecular":[337,523,604],"abnormalities":[338],"follows:":[341],"61%":[342],"(n=57)":[343],"complex":[345],"cytogenetics,":[346],"(n=10)":[348],"FLT3":[350],"mutation":[351],"(ITD":[352],"TKD),":[354],"9%":[355],"(n=8)":[356],"NPM1":[358],"mutation,":[359,364],"35%":[360,446],"(n=33)":[361],"TP53":[363],"19%":[366],"(n=18)":[367],"IDH1/":[369],"IDH2":[370],"mutation.":[371],"subset":[374],"25":[376],"whom":[379],"lines":[382,405],"prior":[385,396,404,411],"available,":[391],"28%":[392,407],"(n=7)":[393,408],"1":[395],"line":[397],"therapy,":[399],"44%":[400],"(n=11)":[401],"2":[403],"lines.":[412],"15":[428],"months":[429,499],"2-17":[431],"months).":[432],"Of":[433],"75":[434],"evaluable":[435],"patients,":[436],"26":[437],"achieved":[438,545],"CR,":[440,563],"(95%":[447,456,467,476,491,500],"CI":[448,457,468,477,492,501],"24-47%).":[449],"MRD-negative":[451],"24%":[455],"15-35%,":[458],"n=18)":[459],"MRD-positive":[462],"11%":[466],"5-20%,":[469],"n=8).":[470],"4%":[475],"1-11%,":[478],"n=3),":[479],"MLFS":[488],"47%":[490],"35-59%,":[493],"n=35).":[494],"8":[498],"6-10":[502],"months),":[503],"1-year":[505],"2-year":[507],"33%":[511],"16%,":[513],"respectively.":[514],"There":[515],"no":[517],"associations":[518],"between":[519,600],"profile":[524,605],"type":[526,607],"Age":[529],"(median":[535],"[IQR]":[536],"65":[549],"[61-72]":[550],"versus":[552],"58":[553],"[48-69]":[554],"did":[559,595],"achieve":[561],"p=0.05).":[564],"CONCULSIONS:":[565],"comparable":[580],"historical":[582],"other":[587],"regimens":[588],"used":[589,617],"treat":[591],"find":[597],"an":[598],"AML,":[609],"suggesting":[610],"that":[611,630,649],"can":[615],"be":[616],"broadly":[618],"setting.":[621],"Further":[622],"prospective":[623],"studies":[624],"needed":[626],"determine":[628],"populations":[629],"may":[631,650],"benefit":[632],"most":[633],"regimen":[636],"additional":[638],"outcomes":[639],"such":[640],"duration":[646],"guide":[651],"decision":[653],"making.":[654]},"counts_by_year":[],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2022-11-30T00:00:00"}